The ascendancy of Viagra and its effect on the medicinal landscape presents a complicated question for shareholders. While the initial sales figures were impressive, the intellectual property has lapsed, leading to a deluge of generic alternatives that are chipping away at earnings. Furthermore, the sector is facing challenges related to demographi